Product Description: Lifirafenib (BGB-283) is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRafV600E and EGFR, respectively.
Applications: Cancer-Kinase/protease
Formula: C25H17F3N4O3
References: [1]Tang Z, et al. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Mol Cancer Ther. 2015 Oct;14(10):2187-97.
CAS Number: 1446090-79-4
Molecular Weight: 478.42
Compound Purity: 98.73
Research Area: Cancer
Solubility: DMSO : ≥ 100 mg/mL
Target: EGFR;Raf